Research Analysts Set Expectations for HOWL Q1 Earnings

Key Points

• Leerink Partners estimates Werewolf Therapeutics will report Q1 2026 earnings of **($0.39)** per share, with an overall consensus estimate for the full year at **($1.56)** EPS.
• Bank of America decreased its price objective for Werewolf Therapeutics from **$9.00** to **$8.00**, maintaining a "buy" rating, while other analysts have varied target prices between **$3.00** and **$8.00**.
• Institutional investors hold **64.84%** of Werewolf Therapeutics' shares, with significant new positions taken by Jane Street Group and Deutsche Bank AG.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for shares of Werewolf Therapeutics in a report issued on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings per share of ($0.39) for the quarter. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics' Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.45) EPS and Q4 2026 earnings at ($0.51) EPS.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10.

A number of other brokerages also recently issued reports on HOWL. Citigroup restated a "buy" rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. JMP Securities cut their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a report on Thursday, August 21st. Finally, Bank of America cut their price target on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a report on Monday, August 25th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Werewolf Therapeutics has a consensus rating of "Buy" and an average target price of $8.00.

Werewolf Therapeutics Price Performance

HOWL traded up $0.09 during trading on Friday, reaching $1.46. The company's stock had a trading volume of 286,258 shares, compared to its average volume of 343,507. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. The firm has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.14. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $4.18. The company has a market cap of $66.54 million, a price-to-earnings ratio of -0.89 and a beta of 0.64.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in HOWL. D. E. Shaw & Co. Inc. acquired a new stake in Werewolf Therapeutics in the 4th quarter valued at approximately $26,000. Quadrature Capital Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Vontobel Holding Ltd. acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at approximately $34,000. Qube Research & Technologies Ltd acquired a new stake in Werewolf Therapeutics in the 2nd quarter valued at approximately $48,000. Finally, Nuveen LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at approximately $71,000. Institutional investors and hedge funds own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.